{"title":"Promising treatments for muscle wasting in cancer: focus on microRNA","authors":"M. Beltrà, P. Costelli, F. Penna","doi":"10.1080/23809000.2016.1209412","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Cancer cachexia is characterized by a progressive loss of body weight and muscle mass, mainly caused by inflammation and anorexia/malnutrition that lead to energy wasting and muscle protein catabolism. These alterations represent the targets of several drugs and multimodal therapeutic approaches that are currently under clinical evaluation. Areas covered: In this review, the molecular mechanisms underlying muscle wasting in cancer and the available treatments are discussed. Afterwards, a particular attention is given to recently discovered new potential targets, focusing mainly on microRNAs, that are emerging as new drivers in the complex scenario of muscle mass control. Expert commentary: Moreover, microRNAs are dysregulated also in cancer, representing an attractive class of molecules for both fighting the tumor and managing cachexia.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"313 - 321"},"PeriodicalIF":0.0000,"publicationDate":"2016-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1209412","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of quality of life in cancer care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23809000.2016.1209412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACT Introduction: Cancer cachexia is characterized by a progressive loss of body weight and muscle mass, mainly caused by inflammation and anorexia/malnutrition that lead to energy wasting and muscle protein catabolism. These alterations represent the targets of several drugs and multimodal therapeutic approaches that are currently under clinical evaluation. Areas covered: In this review, the molecular mechanisms underlying muscle wasting in cancer and the available treatments are discussed. Afterwards, a particular attention is given to recently discovered new potential targets, focusing mainly on microRNAs, that are emerging as new drivers in the complex scenario of muscle mass control. Expert commentary: Moreover, microRNAs are dysregulated also in cancer, representing an attractive class of molecules for both fighting the tumor and managing cachexia.